# Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma

> **NCT02204982** · PHASE3 · TERMINATED · sponsor: **SecuraBio** · enrollment: 13 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Duvelisib
- **DRUG:** Placebo
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02204982
- **Lead sponsor:** SecuraBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2016-12
- **Final completion:** 2017-03
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Sponsor is focusing on studies which can enable registration of duvelisib
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204982, "Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02204982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*